Upadacitinib
Sign in to save this workspacePrimary targets: JAK1 · FDA status: FDA Approved
Selectivity scorecard
KISS
97.98
Gini
0.663
CATDS
0.016
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Upadacitinib. Strongest target: RAF1 at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RAF1 | 99.9% | 0.1% |
| 2 | JAK2 | 98.3% | 1.7% |
| 3 | JAK3 | 97.5% | 2.5% |
| 4 | JAK1 | 97.3% | 2.6% |
| 5 | TYK2 | 97.1% | 2.9% |
| 6 | YSK4_MAP3K19 | 93.4% | 6.6% |
| 7 | STK38L_NDR2 | 91.2% | 8.8% |
| 8 | STK38_NDR1 | 90.8% | 9.2% |
| 9 | PKCA | 84.7% | 15.3% |
| 10 | PKCB2 | 83.3% | 16.7% |
| 11 | C_KIT | 82.9% | 17.1% |
| 12 | PKCD | 78.1% | 21.9% |
| 13 | AURORA_A | 76.7% | 23.3% |
| 14 | PKCG | 75.3% | 24.7% |
| 15 | LRRK2 | 73.3% | 26.7% |
| 16 | TRKC | 70.0% | 30.0% |
| 17 | FLT3 | 69.7% | 30.4% |
| 18 | TAOK2_TAO1 | 67.7% | 32.3% |
| 19 | DDR2 | 67.4% | 32.6% |
| 20 | ARAF | 64.9% | 35.1% |
Selectivity landscape
Where Upadacitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Upadacitinib.
Annotations
Sign in to read and post annotations.
Loading…